DOCSLIB.ORG

Camurus Company Presentation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Camurus Company Presentation Corporate presentation Updated 15 July 2021 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 3 Long-acting medications addressing key healthcare challenges 4 Camurus snapshot Rapidly growing commercial Broad late-stage pipeline stage company • +10 innovative clinical programs in addiction, • Fully operational infrastructure in Europe pain, endocrine disorders and oncology and Australia • Three Phase 3 programs • Buvidal® to date available in 15 countries • Advancing early- and mid-stage candidates • Strong sales performance and growth Market approvals Unique FluidCrystal® Partnerships Experienced Weekly and monthly nanotechnologies R&D collaborations, management & ® Buvidal for opioid • New generation long-acting licensing and royalty dedicated teams dependence depot technology arrangements with • Validated in +25 clinical trials pharmautical and and by approved products biotech companies LISTED ON NASDAQ STO; TICKER CAMX MARKET CAP ~ SEK 11 billion EMPLOYEES: 140 HQ: Lund, Sweden REGIONAL OFFICES: Cambridge, Mannheim, Sydney 5 Leading FluidCrystal® extended-release technology Easy and convenient administration Adopted to prefilled syringes and autoinjectors Rapid onset & long-acting release Manufacturing by standard processes Applicable across substance classes Strong intellectual property Injection of liquid . formulation Encapsulating Slow release Drug release and conc using prefilled H2O liquid crystal gel of drug biodegradation of syringe or triggered by blood gel matrix to full autoinjector water uptake drug resolution time Sources: Tiberg F, et al. Chapter in Long Acting Injections and Implants, Advances in Delivery Science and Technology 2012; Tiberg F, et al. OnDrugDelivery 2010; Tiberg F, et al. Drug Del. Sci. Tech., 21 (1) 101-109 2011. 6 FluidCrystal – Long-acting release Immediate release pasireotide (Signifor®) Pasireotide FluidCrystal® (CAM4071) 10 10 Pasireotide IR 600 ug (SC Pasireotide FluidCrystal 20 thigh, n = 94) mg (SC thigh, n = 12) 1 1 pasireotide plasma concentration (ng/mL) concentration plasma pasireotide pasireotide plasma concentration (ng/mL) concentration plasma pasireotide 0,1 0,1 0 7 14 21 28 0 7 14 21 28 Time (days) Time (days) 7 Weekly and monthly buprenorphine depots Population pharmacokinetic profiles for Buvidal vs sublingual buprenorphine Weekly Buvidal vs. Daily sublingual buprenorphine Weekly vs. Monthly Buvidal Population PK model analysis based on data from four clinical studies (N=236). Diagnostic testing demonstrated predictive buprenorphine concentrations and good agreement between observed and predicted data percentiles. Steady state data. Sources: Abstract presented at the Annual conference of the Society for the Study of Addiction-November 2018; Albayaty M, Linden M, Olsson H, Johnsson M, Strandgarden K, Tiberg F. Adv Ther. 2017;34(2):560–575. 8 Recent business progress •Strong commercial execution with Buvidal ‒ Expanding sales and commercial infrastructure ‒ Initiating diversification and prelaunch preparations for new products •Advancing pipeline ‒ Successful life-cycle management and new regulatory approvals ‒ Two ongoing Phase 3 studies of CAM2029 in acromegaly ‒ Phase 3 study of CAM2029 in neuroendocrine tumors (NET) starting ‒ Brixadi™ NDA filing accepted by FDA with PDUFA date 15 December 2021 ‒ Several early-stage clinical programs and partnerships advancing •Positive financial performance ‒ Strong revenue growth and improved financial results ‒ Solid cash position with no loans ‒ On track for profitability in 2022 1Total revenue SEK 680 – 750 million, whereof product sales SEK 620 – 680 million, and the operating result SEK -120 – 0 million excluding a USD 35 million milestone payment on approval of Brixadi™ in the US 9 Opioid dependence – worsened crisis during the pandemic • Largest society burden of all drugs1 Escalating overdose deaths ‒ High need for better access to care and new during COVID-19 treatment alternatives ‒ Investment in treatment brings substantial value 12 Month-ending Provisional Number and saves lives of Drug Overdose Deaths in the US1 • New funding initiatives 100 000 90 000 All drugs ‒ President Biden recently issued a US$1.5 billion 80 000 initiative for substance use treatment and 70 000 2 Opioids prevention 60 000 ‒ Scottish Government initiative £250m investment 50 000 3 to tackle drug death crisis 40 000 30 000 Start lock-down • Significant limitations with current daily 20 000 medications the in US of deaths Number 10 000 ‒ Diversion, misuse, risk of overdose, poor retention, 0 burdens and stigma of daily buprenorphine and methadone medications 12 month-ending period 1www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm; 10 Buvidal® – flexible long-acting treatment of opioid dependence Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over1 Buvidal provides significant benefits to patients and society “Buvidal became ‒ Improved treatment outcomes and patient satisfaction1-3 my way out” ‒ Reduced treatment burden and improved quality of life2 4 Justin, Buvidal patient in ‒ Diminished diversion, misuse and pediatric exposure Australia ‒ Reduced treatment costs in the criminal justice system5 1Lofwall et al. JAMA Int. Med. 2018;178(6); 764-773; 2Frost et al, Addiction, 2019;114(8):1416-1426; 3Lintzeris N, et al., Results of the DEBUT Study, presented at CPDD Virtual Meeting June 22-24, 2020. 4EPAR; 5Dunlop A, et al. Introduction of Long-Acting Depot Buprenorphine in Prison - the UNLOC-T Study. Presented at CPDD Virtual Meeting June 22-24, 2020 11 Robust Buvidal sales growth continues under pressure by the pandemic Consistent double-digit quarter-by-quarter growth Product sales by quarter (MSEK) ‒ Exceptional uptake in Australia and the Nordics MSEK ‒ Progress in the UK, Germany, Spain and other markets 137 COVID-19 remains a barrier on many markets ‒ 32% 124 Average Q/Q Buvidal market expansion continues growth rate 104 ‒ Available in 15 countries in Europe, Australia and MENA 94 ‒ P&R applications in new markets 76 ‒ 8 launches planned in 2021 49 Successful life-cycle management and growing 30 scientific evidence 20 ‒ New approvals and important scientific publications Increasing media coverage ‒ Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2019 2020 2021 MENA; – Middle East and North Africa; P&R – price and reimbursement 12 Buvidal market expansion continues Netherlands Switzerland ~10,000 patients in opioid 10,000 patients1 dependence treatment1 Marketing approval received Launch expected in Q3 2021 Launch expected in Q3 2021 France Croatia and Slovenia 1 >179,000 patients1 >8,000 patients Positive HEOR assessment by Preparing for launch Q3 2021 Haute Autorité de Santé Preparing for launch in Q3 2021 Italy ~70,000 patients1 Portugal PMA ongoing >17,000 patients1 Preparing for launch in Q3 2021 New Zealand ~5,500 patients2,3 MENA Launch sequence Market authorization received Early access program in three countries Wave 1& 2 Wave 3 markets PMA initiated Several regulatory submissions Launched Wave 4 markets progressing 1EMCDDA 2020; 2Office of the Director of Mental Health and Addiction Services Annual Report 2018 and 2019; 3New Zealand Practice Guidelines for Opioid Substitution Treatment 2014 13 Increasing support for Buvidal and improved access to innovative ODT treatments •Government initiatives to increase •Growing scientific evidence base funding and improve treatment access ‒ Positive results in peer-reviewed ‒ Scottish government and Public Health scientific journals England allocating funding for ODT and ‒ Affirmative “real world” outcome Buvidal1,2 studies ‒ Recommendation for significant investments ‒ Health-economical assessments in ODT and innovations in England3 demonstrating value of Buvidal to ‒ Processes ongoing in Germany and Sweden payors and society to improve HCP remuneration system •Increasing media attention •Adoption in the criminal justice system ‒ Unmet medical need and positive ‒ Expanding use of Buvidal with Australia, impact of ODT Germany and Scotland as forerunners ‒ Strong testimonials by patients ‒ Benefits of Buvidal clearly recognized, and HCPs including cost savings ‒ Buvidal identified as “game-changer” ‒ Estimated >100,000 people with opioid dependence in European prisons4 1https://www.gov.scot/publications/evaluation-opioid-substitution-treatment-scotlands-prisons-covid-19-contingency-patient-experience-follow-up-report/
Load more

Recommended publications
  • CAM2038 Weekly Opioid Dependence
    Cowen & Co. Annual Health Care Conference 2017 Camurus Advancing late stage pipeline with high market potential Company Presentation, 7 March 2017 Forward-looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 2 Camurus overview LISTED ON NASDAQ STOCKHOLM • Innovation that delivers 3rd DEC, 2015 − Proprietary FluidCrystal® technology used in 10 clinical programs − Preclinical to NDA/MAA enabling MARKET CAP pipeline programs − Expansive and rewarding pharma partnerships
    [Show full text]
  • Company Presentation
    Company presentation November 2020 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements Long-acting medications addressing key healthcare challenges 4 Corporate highlights Rapidly growing commercial Broad late-stage pipeline stage company • +10 innovative clinical programs in • Fully operational infrastructure in Europe addiction, pain, oncology, endocrine and Australia disorders and CV diseases • Buvidal® to date launched in 9 countries • Two ongoing
    [Show full text]
  • Camurus Company Presentation Cowen 2020
    Company Presentation Cowen & Co. 40th Annual Health Care Conference 2 March 2020, Boston, MA Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 2 LISTED ON NASDAQ STO; TICKER CAMX MARKET CAP Camurus in brief ~ SEK 4.5 billion EMPLOYEES: 130 HQ: Lund, Sweden REG. OFFICES: Cambridge, Mannheim, Sydney, Paris ® Unique FluidCrystal Two Phase 3 programs nanotechnologies • Late-stage pipeline with 10 innovative • In-house developed with strong IP clinical
    [Show full text]
  • Invitation to Subscribe for Shares in Camurus AB
    Invitation to subscribe for shares in Camurus AB Please note that the subscription rights are expected to have an economic value. In order to not lose the value of the subscription rights, holders must either: • Exercise the subscription rights received and subscribe for new shares no later than 25 March 2019, or • Sell the subscription rights received, but not exercised, no later than 21 March 2019. Please note that shareholders with nominee-registered shareholdings subscribe for new shares through their custodian/nominee. The distribution of this prospectus and the subscription for new shares are subject to restrictions in certain jurisdictions (see “Selling and transfer restrictions”). FINANCIAL ADVISORS IMPORTANT INFORMATION For certain definitions used in this prospectus, see “Certain definitions” on the next page. A Swedish version of this prospectus has been approved and registered by the Swedish Financial Supervisory Authority (the “SFSA”) in accordance with Chapter 2, sections 25 and 26 of the Swedish Financial Instruments Trading Act (lagen (1991:980) om handel med finansiella instrument). Approval and registration does not imply that the SFSA guarantees that the information in the prospectus is accurate or complete. The prospectus and the offering hereunder are governed by Swedish law. Disputes arising in connection with this prospectus, the offering and related legal matters shall be settled exclusively by Swedish courts. The prospectus has been prepared in both Swedish and English language versions. In the event of any conflict between the versions, the Swedish version shall prevail. Camurus has not taken, and will not take any actions to allow a public offering in any jurisdiction other than Sweden.
    [Show full text]
  • Camurus Had an Excellent Start of 2021 with Strong Revenue Growth, New Regulatory Approvals and Progress in the Pipeline”
    INTERIM REPORT FOR THE FIRST QUARTER 2021 “Camurus had an excellent start of 2021 with strong revenue growth, new regulatory approvals and progress in the pipeline” Camurus is an international science-led biopharmaceutical company committed to developing and commercializing innovative medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the unique proprietary FluidCrystal® drug delivery technologies and its extensive R&D and sales expertise. Camurus’ clinical pipeline includes product candidates for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. Camurus’ share is listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit camurus.com First quarter summary Q1 • Total revenue amounted to SEK 126 (49) million, an increase of 155% (161% at CER1) • Product sales were SEK 124 (49) million, an increase of 156% (162% at CER) • Sales growth was 20% (18% at CER) compared to the previous quarter Total revenue • Market approval for Buvidal in New Zealand SEK 126 million • CHMP recommended approval of a new 160mg dose of Buvidal in the EU +155% • Buvidal launched in Spain and the first hundred patients received treatment • Positive decision from health economic evaluation of Buvidal by Haute Autorité de Santé in France Product sales • FDA issued Safe to Proceed letter for the start of a Phase 3 study of CAM2029 for the treatment of SEK 124 million neuroendocrine tumors +156% • Scientific advice with FDA regarding the clinical program for CAM2029 for polycystic liver disease • New patent issued for CAM2038 Weekly in the US with patent term until July 2032 Operating result • The financial outlook for 2021 is unchanged; total revenue SEK 680 – 750 million2, SEK -26 million whereof product sales SEK 620 – 680 million, and the operating result SEK -120 – 0 million2 +66% 1) At constant exchange rates in January 2021.
    [Show full text]
  • Solasia Acquires Exclusive License and Distribution Rights from Camurus for Episil® Oral Liquid in Japan and China
    Camurus AB Press release Ideon Science Park SE-223 70 Lund, Sweden www.camurus.com Phone: +46 46 286 57 30 Solasia acquires exclusive license and distribution rights from Camurus for episil® oral liquid in Japan and China Lund, Sweden, and Tokyo, Japan — March 30, 2015 — Camurus AB (“Camurus”) and Solasia Pharma K.K. (“Solasia”) jointly announced today that they have entered into a license and distribution agreement for episil® oral liquid, a unique and effective treatment for the pain of oral mucositis, a treatment-limiting side effect of some cancer therapies, as well as other oral lesions. As part of the agreement Solasia receives exclusive commercialization rights to episil® in Japan and China, where it has ongoing operations and is building a specialty pharmaceutical infrastructure in the area of oncology and cancer supportive care. Solasia plans to first launch episil® in China followed by Japan. “We are pleased to enter into this collaboration with Camurus, and for the opportunity to commercialize episil® in Japan and China” said Yoshihiro Arai, President and Representative Director of Solasia. “Solasia specializes in innovative oncology treatments, and episil® will take its place as one of the core products in our oncology pipeline”, he continued, noting that episil® fills an important unmet need in daily pain management associated with cancer care, and will contribute to improved quality of life for cancer patients in Japan and China. “The new partnership with Solasia expands Camurus’ distributor network for episil® oral liquid in two of the key markets in Asia”, said Fredrik Tiberg, President and CEO of Camurus.
    [Show full text]
  • Pipeline Progress
    Second quarter results 2020 Audiocast presentation 16 July 2020 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 3 Agenda • Second quarter 2020 overview Company participants • Buvidal progress in EU & Australia Fredrik Tiberg, PhD President & CEO, Head R&D • Pipeline update • Key take-aways Eva Pinotti Lindqvist • Revised Outlook 2020 Chief Financial Officer • Q&A Richard Jameson Chief Commercial Officer 4 Continued strong performance in the second
    [Show full text]
  • Fourth Quarter & Full Year Results 2019
    Fourth quarter & full year results 2019 12 February 2020 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 2 Agenda • Fourth quarter 2019 overview Participants • Buvidal progress in EU & Australia Fredrik Tiberg, PhD • US approval and launch status President & CEO, Head R&D • R&D pipeline update • Key take-aways Eva Pinotti Lindqvist Chief Financial Officer • Q&A 3 Financial overview Financials Q4 2019 FY 2019 2019 Product sales 2020 Guidance FY 2020 MSEK MSEK MSEK 80 72.1 *) Net revenue 35.0 (7.8) 105.6 (49.3) 70 Total revenues 290 – 330 60 – product sales 240 – 280 – product sales 30.3 (5.1) 72.1 (11.3) 50 41.9 OPEX 570 – 610 Operating 40 result -88.4 (-103.2) -360.0 (-287.2) MSEK *) 30 excl.
    [Show full text]
  • Brixadi™In the US
    Company presentation July 2020 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements Long-acting medications addressing key healthcare challenges 4 Corporate highlights Rapidly growing commercial Broad late-stage pipeline stage company • 10 innovative clinical programs in • Fully operational commercial addiction, pain, oncology, endocrine infrastructure in Europe and Australia disorders and CV diseases • Buvidal® to date launched in 8 countries • Two
    [Show full text]
  • Covid-19 Causing Spike in Opioid Overdoses
    Company presentation November 2020 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements Long-acting medications addressing key healthcare challenges 4 Corporate highlights Rapidly growing commercial Broad late-stage pipeline stage company • +10 innovative clinical programs in • Fully operational infrastructure in Europe addiction, pain, oncology, endocrine and Australia disorders and CV diseases • Buvidal® to date launched in 10 countries • Two ongoing
    [Show full text]
  • Annual Report 2015 Contents This Is Camurus
    INNOVATIVE NANOSCALE THERAPEUTICS ANNUAL REPORT 2015 CONTENTS THIS IS CAMURUS This is Camurus ................................................................................................ 1 Leading innovation Key performance indicators ............................................................. 2 • FluidCrystal® – award-winning drug delivery technology 2015 In brief ......................................................................................................... 3 • Broad and advanced product pipeline Statement from the CEO ...................................................................... 4 • More than 400 patents and patent applications Operating environment........................................................................ 6 Strategy..................................................................................................................... 7 The patient in focus Technology platforms ..........................................................................10 • Simple and flexible administration Our development portfolio ..........................................................14 • Long-acting formulations for improved compliance Marketing organisation ......................................................................18 • Improved treatment outcomes and quality of life Employee portraits ..................................................................................20 Our development portfolio, cont. .........................................21 Strategic partnerships Early R&D projects ....................................................................................26
    [Show full text]
  • 2018 Otte, Liquid Crystalline Drug Delivery Vehicles for Oral and IV
    International Journal of Pharmaceutics 539 (2018) 175–183 Contents lists available at ScienceDirect International Journal of Pharmaceutics journal homepage: www.elsevier.com/locate/ijpharm Liquid crystalline drug delivery vehicles for oral and IV/subcutaneous T administration of poorly soluble (and soluble) drugs ⁎ Andrew Ottea, , Bong-Kwan Sohb, Gwangheum Yoonb, Kinam Parka,c a Purdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA b Chong Kun Dang Research Institute, 315-20, Dongbaekjukjeondaero, Giheung-gu, Youngin-si, Gyeonggi-do 16995, South Korea c Purdue University, Department of Industrial and Physical Pharmacy, West Lafayette, IN 47907, USA ARTICLE INFO ABSTRACT Keywords: Poorly soluble drug molecules often have low bioavailability issues and absorption problems in the clinical Liquid crystal setting. As the number of poorly soluble drugs increases from discovery, developing technologies to enhance Drug delivery their solubility, while also controlling their release is one of the many challenges facing the pharmaceutical Cubosome industry today. Liquid crystalline systems, nanoparticulate or macro-matrix, self-assemble in the presence of an Hexosome aqueous environment and can provide a solubility enhancement, while also controlling the drug release rate. Poorly soluble drug This review examines the fundamentals of liquid crystalline systems through the representative literature, concluding with examples of liquid crystalline systems in clinical trials development. The review focus is on the potential of utilizing liquid crystalline systems for poorly soluble drugs, in the areas of oral delivery and IV/ subcutaneous, followed by water soluble molecules. Key considerations in utilizing liquid crystalline systems advantages while also discussing potential areas of key research that may be needed will be highlighted.
    [Show full text]